Christine Ambrose

Medicine · Health Sciences

35h-index9.5kcitations70works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(19), T-cell and B-cell Immunology(18), Immunotherapy and Immune Responses(13), Immune Cell Function and Interaction(11), Virus-based gene therapy research(10)

Publications70 total

334 CAR T engagers encoding immune checkpoint inhibitors and immune-relevant cytokines stimulate CAR T cell activity against hematologic and solid tumors
Regular and Young Investigator Award Abstracts·2023Open Access
A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2+ Solid Cancer
Cells·2023· 3 citedOpen Access
175 CAR-T engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
Regular and Young Investigator Award Abstracts·2022Open Access
CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
OncoImmunology·2022· 5 citedOpen Access
Abstract 2759: CAR-T engager proteins for the treatment of B cell cancers and acute myeloid leukemia
Cancer Research·2022
CAR-T Engager Proteins Optimize Anti-CD19 CAR-T Cell Therapies for Lymphoma
2022Open Access
Characterization of Aleta-001, a CAR T Engager Designed to Optimize Responses and Prevent Relapses from CAR-19 Therapy
Blood·2021
160 Evaluation and development of dual and triple antigen targeting CAR-T Engager proteins for Her2-positive CNS metastases and solid tumors
Regular and Young Investigator Award Abstracts·2021· 1 citedOpen Access
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
PLoS ONE·2021· 22 citedOpen Access
133 Development of novel cellular therapeutics for metastatic and primary CNS malignancies
Regular and Young Investigator Award Abstracts·2020Open Access
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
2020Open Access
Abstract B020: CAR-CD19 T cells secreting multi-antigen bridging proteins eliminate solid tumors
Molecular Cancer Therapeutics·2019
A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment In Vivo
Blood·2019· 9 cited
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins
Molecular Pharmaceutics·2019· 41 cited
Abstract A040: Hijacking CAR19 T-cells for use in targeting diverse hematopoietic and solid tumors
Cancer Immunology Research·2019· 1 cited
Abstract 2569: CAR19 T cells secreting antigen-retargeting fusion proteins have remarkable potency against diverse tumor types
Cancer Research·2018· 1 cited
Activity of CAR19 T cells secreting impact fusion proteins against hematopoietic and solid tumors.
Journal of Clinical Oncology·2018· 2 cited
CAR19 T Cells Redirected to Novel Antigens Mediate Robust Cytotoxicity Against Diverse Malignancies
Blood·2017· 1 cited
Abstract 3768: CAR T cells specific for CD19 can be redirected to kill CD19 negative tumors
Cancer Research·2017· 4 cited
Poly(GP) proteins are a useful pharmacodynamic marker for <i>C9ORF72</i> -associated amyotrophic lateral sclerosis
Science Translational Medicine·2017· 266 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Sarah A. Bixler(12), Susan L. Kalled(9), Fabienne Mackay(8), Jeffrey L. Browning(8), Jeffrey S. Thompson(8), James F. Gusella(8), Mabel P. Duyao(7), Marcy E. MacDonald(7), Lihe Su(7), Pascal Schneider(6), Jürg Tschopp(6), Paul D. Rennert(6), Yen‐Ming Hsu(6), Minou Bina(6), Sandra McNeil(5), Roy R. Lobb(5), Fang Qian(4), Teresa G. Cachero(4), Christopher D. Benjamin(4), Linda C. Burkly(4)